Holen Sie sich die Stockscreener-App
15.27
5.97%
0.86
Vorhandelsmarkt:
15.27
Schlusskurs vom Vortag:
$14.41
Offen:
$14.6
24-Stunden-Volumen:
429.96K
Relative Volume:
1.86
Marktkapitalisierung:
$397.81M
Einnahmen:
$31.38M
Nettoeinkommen (Verlust:
$-6.69M
KGV:
-58.73
EPS:
-0.26
Netto-Cashflow:
$-1.84M
1W Leistung:
+13.79%
1M Leistung:
+21.48%
6M Leistung:
+336.29%
1J Leistung:
+268.84%
1-Tages-Spanne:
$14.55
$15.71
1-Wochen-Bereich:
$13.09
$15.71
52-Wochen-Spanne:
$3.03
$15.71
Eton Pharmaceuticals Inc Stock (ETON) Company Profile
Firmenname
Eton Pharmaceuticals Inc
Sektor
Telefon
(847) 787-7361
Adresse
21925 W. FIELD PARKWAY, DEER PARK, IL
Vergleichen Sie ETON mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ETON
Eton Pharmaceuticals Inc
|
15.27 | 397.81M | 31.38M | -6.69M | -1.84M | -0.26 |
|
ZTS
Zoetis Inc
|
167.53 | 75.58B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.24 | 41.78B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.10 | 41.53B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
21.82 | 24.72B | 16.77B | -959.00M | 1.37B | -0.85 |
|
NBIX
Neurocrine Biosciences Inc
|
145.88 | 14.77B | 2.24B | 385.90M | 440.10M | 3.73 |
Eton Pharmaceuticals Inc Stock (ETON) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-10 | Eingeleitet | B. Riley Securities | Buy |
| 2025-01-06 | Bestätigt | H.C. Wainwright | Buy |
| 2024-09-04 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-05-06 | Eingeleitet | Craig Hallum | Buy |
| 2021-10-14 | Fortgesetzt | B. Riley Securities | Buy |
| 2021-01-04 | Bestätigt | H.C. Wainwright | Buy |
| 2019-09-20 | Eingeleitet | B. Riley FBR | Buy |
| 2019-06-10 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Eton Pharmaceuticals Inc Aktie (ETON) Neueste Nachrichten
Eton Pharmaceuticals stock soars to all-time high of $15.11 - MSN
Eton acquires Wilson disease drug Galzin - MSN
14 Best 52-Week High Stocks To Buy According to Analysts - Insider Monkey
Eton Pharmaceuticals, Inc. (ETON): Analysts Recommend This 52-Week High Stocks Now - Insider Monkey
15,006 Shares in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Acquired by Jane Street Group LLC - Defense World
Q1 Earnings Estimate for ETON Issued By B. Riley - Defense World
Q1 Earnings Forecast for ETON Issued By B. Riley - MarketBeat
Eton Pharmaceuticals (NASDAQ:ETON) Upgraded at B. Riley - Defense World
Eton Pharmaceuticals (NASDAQ:ETON) Coverage Initiated at B. Riley - Defense World
Eton Pharmaceuticals (NASDAQ:ETON) Raised to "Strong-Buy" at B. Riley - MarketBeat
When the Price of (ETON) Talks, People Listen - Stock Traders Daily
B. Riley Begins Coverage on Eton Pharmaceuticals (NASDAQ:ETON) - MarketBeat
Craig Hallum Forecasts Strong Price Appreciation for Eton Pharmaceuticals (NASDAQ:ETON) Stock - Defense World
HC Wainwright Issues Positive Forecast for ETON Earnings - Defense World
Q2 EPS Estimate for Eton Pharmaceuticals Lifted by Analyst - MarketBeat
Investing in Eton Pharmaceuticals (NASDAQ:ETON) three years ago would have delivered you a 177% gain - Yahoo Finance
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Position Boosted by Geode Capital Management LLC - Defense World
What is HC Wainwright’s Forecast for ETON FY2027 Earnings? - Defense World
Eton Pharmaceuticals’ Acquisition of Galzin® - Global Legal Chronicle
Eton Pharmaceuticals (NASDAQ:ETON) Price Target Raised to $18.00 at Craig Hallum - MarketBeat
The Analyst Verdict: Eton Pharmaceuticals In The Eyes Of 5 Experts - Benzinga
What is HC Wainwright's Forecast for ETON FY2027 Earnings? - MarketBeat
Eton Pharmaceuticals (NASDAQ:ETON) Price Target Raised to $17.00 - MarketBeat
Eton Pharmaceuticals (NASDAQ:ETON) versus Repare Therapeutics (NASDAQ:RPTX) Financial Survey - Defense World
Eton Pharmaceuticals Acquires FDA-Approved Zinc Treatment for Wilson Disease - Defense World
ETONEton Pharmaceutcials, Inc. Latest Stock News & Market Updates - StockTitan
Eton Pharmaceuticals stock soars to all-time high of $14.05 By Investing.com - Investing.com Australia
Eton acquires Wilson disease drug Galzin (ETON:NASDAQ) - Seeking Alpha
Eton Pharmaceuticals Advances Its Commitment to Rare Disease with the Acquisition of Galzin® - GlobeNewswire
Eton Pharmaceuticals Acquires FDA-Approved Wilson Disease Treatment Galzin, Expands Rare Disease Portfolio - StockTitan
Eton Pharmaceuticals Advances Its Commitment to Rare Disease with the Acquisition of Galzin - Business Upturn
Eton Pharmaceuticals stock soars to all-time high of $14.05 - Investing.com India
Tesla Inc (TSLA-Q) QuotePress Release - The Globe and Mail
When (ETON) Moves Investors should Listen - Stock Traders Daily
Individual investors who hold 55% of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) gained 11%, institutions profited as well - Simply Wall St
Eton Pharmaceuticals (NASDAQ:ETON) Completes Acquisition of Increlex® from Ipsen S.A. - Defense World
Where are the Opportunities in (ETON) - Stock Traders Daily
Eton Pharmaceuticals, Inc. completed the acquisition of Increlex® from Ipsen Biopharmaceuticals, Inc. - Marketscreener.com
Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection) - The Manila Times
Eton Pharmaceuticals Acquires Rare Growth Disorder Drug Increlex, Expanding Pediatric Treatment Portfolio - StockTitan
Eton Pharmaceuticals Announces Positive Results from Clinical Trial for PKU GOLIKE Protein Substitute - Defense World
Eton Pharmaceuticals Announces Final Readout of PKU GOLIKE® Clinical Trial - The Manila Times
Eton Pharma's PKU GOLIKE Clinical Trial Shows Breakthrough Results in Metabolic Control - StockTitan
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Short Interest Up 32.6% in November - MarketBeat
Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) top owners are retail investors with 58% stake, while 26% is held by institutions - Yahoo Finance
EcoR1 Capital, LLC Increases Stake in Eton Pharmaceuticals Inc. - GuruFocus.com
The Escalator: AstraZeneca, Eton Pharmaceuticals, AltruBio and more - MM+M Online
Eton Pharmaceuticals Appoints Ipek Erdogan-Trinkaus as Chief Commercial Officer - GlobeNewswire
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Sees Significant Increase in Short Interest - Defense World
Finanzdaten der Eton Pharmaceuticals Inc-Aktie (ETON)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.14%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):